Aurobindo Pharma Ltd., on Thursday, said that the United States Food and Drug Administration (USFDA) had lifted the import alert on its antibiotics facility, paving the way for resumption of exports of nine products to the U.S. market.

In a filing, Aurobindo Pharma informed the BSE that the USFDA, as per its website update, lifted import alert for non-sterile products manufactured in Aurobindo’sUnit-VI cephalosporin facility based in Hyderabad.

The import alert was imposed in February 2011. Aurobindo Pharma had annual sales of $33 million from the products manufactured in the unit prior to the alert.